Overview

Somatuline Predictive Factors in Acromegaly and NET

Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
0
Participant gender:
All
Summary
The aim of the study is to identify predictive factors for the response to Lanreotide treatment in Acromegaly as well as in Neuroendocrine Tumours.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ipsen
Treatments:
Angiopeptin
Lanreotide
Somatostatin
Criteria
Inclusion Criteria:

- Written informed consent (also mandatory in case of retrospective documentation of
subject data)

- Diagnosis of acromegaly or NET with the intention to be treated with ATG or already on
treatment with ATG

Exclusion Criteria:

- The subject has already been included in this study

- Participation in an interventional trial